Cargando…

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience

BACKGROUND: Thyroid gland nodules are common and fine-needle aspiration (FNA) is the gold standard for screening those nodules. The Bethesda system for reporting thyroid cytolopathology standardized reporting thyroid nodules aspirations, but atypia of undetermined significance or follicular lesion o...

Descripción completa

Detalles Bibliográficos
Autores principales: Almahari, Sayed Ali, Harb, Zainab, Alshaikh, Safa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764167/
https://www.ncbi.nlm.nih.gov/pubmed/31576199
http://dx.doi.org/10.4103/cytojournal.cytojournal_4_19
_version_ 1783454321687396352
author Almahari, Sayed Ali
Harb, Zainab
Alshaikh, Safa
author_facet Almahari, Sayed Ali
Harb, Zainab
Alshaikh, Safa
author_sort Almahari, Sayed Ali
collection PubMed
description BACKGROUND: Thyroid gland nodules are common and fine-needle aspiration (FNA) is the gold standard for screening those nodules. The Bethesda system for reporting thyroid cytolopathology standardized reporting thyroid nodules aspirations, but atypia of undetermined significance or follicular lesion of undetermined significance (Bethesda category III) was the most controversial category. The aim of our study is to review our institutional experience and analyze the clinical implications of making a diagnosis of AUS/FLUS (Bethesda category III). METHODS: This is a retrospective study of an 889 thyroid FNAs from 825 patients in Salmaniya Medical Complex, during (January 2013–December 2017). RESULTS: The most common cause for designating cases as AUS/FLUS (Bethesda category III) was the presence of features suggestive of papillary thyroid carcinoma, but not quite fulfilling the criteria for such diagnosis. Ninety-six cases were diagnosed as AUS/FLUS (10.7%), in which 26 (27%) patients underwent surgery without repeating the FNA, 25 (26%) underwent a second FNA and 43 (44.7%) patients were followed up by ultrasound. On repeating the FNA, 1 (4%) was unsatisfactory, 13 (52%) were benign, 10 (40%) were AUS/FLUS, and only 1 (4%) was categorized as malignant. Thirty cases were surgically excised, in which 4 (13.3%) were diagnosed as follicular adenoma, 2 (6.6%) as Hurthle cell adenoma, 9 (30%) as multinodular goiter, 5 (16.6%) as multinodular goiter with Hashimoto thyroiditis, 1 (3.3%) as colloid nodule with Hashimoto thyroiditis, and 9 (30%) as papillary thyroid carcinoma. Among all the cases diagnosed initially as AUS/FLUS (Bethesda category III), 9 (9.3%) cases were diagnosed as papillary thyroid carcinoma. CONCLUSION: Diagnostically, we almost meet the international standards of designating cases with AUS/FLUS (Bethesda category III) and approximate the risk of malignancy. However, the clinical management's guidelines should be followed to decrease the risk of unnecessary surgeries and their complications. There is a statistically significant correlation between the age and gender with the final histopathology report, respectively.
format Online
Article
Text
id pubmed-6764167
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-67641672019-10-01 Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience Almahari, Sayed Ali Harb, Zainab Alshaikh, Safa Cytojournal Research Article BACKGROUND: Thyroid gland nodules are common and fine-needle aspiration (FNA) is the gold standard for screening those nodules. The Bethesda system for reporting thyroid cytolopathology standardized reporting thyroid nodules aspirations, but atypia of undetermined significance or follicular lesion of undetermined significance (Bethesda category III) was the most controversial category. The aim of our study is to review our institutional experience and analyze the clinical implications of making a diagnosis of AUS/FLUS (Bethesda category III). METHODS: This is a retrospective study of an 889 thyroid FNAs from 825 patients in Salmaniya Medical Complex, during (January 2013–December 2017). RESULTS: The most common cause for designating cases as AUS/FLUS (Bethesda category III) was the presence of features suggestive of papillary thyroid carcinoma, but not quite fulfilling the criteria for such diagnosis. Ninety-six cases were diagnosed as AUS/FLUS (10.7%), in which 26 (27%) patients underwent surgery without repeating the FNA, 25 (26%) underwent a second FNA and 43 (44.7%) patients were followed up by ultrasound. On repeating the FNA, 1 (4%) was unsatisfactory, 13 (52%) were benign, 10 (40%) were AUS/FLUS, and only 1 (4%) was categorized as malignant. Thirty cases were surgically excised, in which 4 (13.3%) were diagnosed as follicular adenoma, 2 (6.6%) as Hurthle cell adenoma, 9 (30%) as multinodular goiter, 5 (16.6%) as multinodular goiter with Hashimoto thyroiditis, 1 (3.3%) as colloid nodule with Hashimoto thyroiditis, and 9 (30%) as papillary thyroid carcinoma. Among all the cases diagnosed initially as AUS/FLUS (Bethesda category III), 9 (9.3%) cases were diagnosed as papillary thyroid carcinoma. CONCLUSION: Diagnostically, we almost meet the international standards of designating cases with AUS/FLUS (Bethesda category III) and approximate the risk of malignancy. However, the clinical management's guidelines should be followed to decrease the risk of unnecessary surgeries and their complications. There is a statistically significant correlation between the age and gender with the final histopathology report, respectively. Wolters Kluwer - Medknow 2019-09-16 /pmc/articles/PMC6764167/ /pubmed/31576199 http://dx.doi.org/10.4103/cytojournal.cytojournal_4_19 Text en Copyright: © 2019 Almahari, et al.; Licensee Cytopathology Foundation Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Research Article
Almahari, Sayed Ali
Harb, Zainab
Alshaikh, Safa
Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
title Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
title_full Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
title_fullStr Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
title_full_unstemmed Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
title_short Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
title_sort evaluation of thyroid nodules classified as bethesda category iii on cytology and their malignancy rate: an institutional experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764167/
https://www.ncbi.nlm.nih.gov/pubmed/31576199
http://dx.doi.org/10.4103/cytojournal.cytojournal_4_19
work_keys_str_mv AT almaharisayedali evaluationofthyroidnodulesclassifiedasbethesdacategoryiiioncytologyandtheirmalignancyrateaninstitutionalexperience
AT harbzainab evaluationofthyroidnodulesclassifiedasbethesdacategoryiiioncytologyandtheirmalignancyrateaninstitutionalexperience
AT alshaikhsafa evaluationofthyroidnodulesclassifiedasbethesdacategoryiiioncytologyandtheirmalignancyrateaninstitutionalexperience